MedTrace Logo

The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial

NCT00217256 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 436

Last updated 2011-06-27

No results posted yet for this study

Summary

To demonstrate the equivalency in in-segment late lumen loss at 8 months between the Endeavor Drug Eluting Coronary Stent System coated with ABT-578 (10 micrograms/mm) and the Cypher Sirolimus-Eluting Coronary Stent System for the treatment of single de novo lesions in native coronary arteries 2.5-3.5 mm in diameter.

Conditions

Interventions

DEVICE

Percutaneous Coronary Stenting

Endeavor Drug Eluting Stent

DEVICE

Percutaneous Coronary Stenting

Cypher Drug Eluting Stent

Sponsors & Collaborators

  • Medtronic Vascular

    lead INDUSTRY

Principal Investigators

  • Martin B. Leon, M.D. · Columbia University College of Physicians & Surgeons

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2005-05-31
Completion
2010-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00217256 on ClinicalTrials.gov